57070-77-6

Basic information

• Product Name: 2-bromo-5-methoxythiophene
• Synonyms: 2-bromo-5-methoxythiophene
• CAS NO: 57070-77-6
• Molecular Formula: C5H5BrOS
• Molecular Weight: 193.064
• Mol File: 57070-77-6.mol

Chemical Properties

• Boiling Point: 92-93 °C(Press: 19 Torr)
• Appearance: /
• Density: 1.623 g/cm3(Temp: 26 °C)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2-bromo-5-methoxythiophene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-5-methoxythiophene(57070-77-6)
• EPA Substance Registry System: 2-bromo-5-methoxythiophene(57070-77-6)

Safety Data

• Hazardous Substances Data: 57070-77-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-bromo-5-methoxythiophene is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be readily incorporated into complex molecular structures. Its unique combination of bromine and methoxy groups allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2-bromo-5-methoxythiophene is utilized as a precursor in the production of pesticides and other agrochemicals. Its reactivity and functional groups enable the creation of compounds with targeted pest control capabilities, contributing to more effective and sustainable agricultural practices.
Used in Material Science:
2-bromo-5-methoxythiophene is employed as a building block in the development of advanced materials, such as polymers and composites, due to its chemical properties and reactivity. Its incorporation into these materials can enhance their performance characteristics, such as stability, durability, and specific functional properties.
Used in Chemical Research:
As a versatile compound, 2-bromo-5-methoxythiophene is also used in chemical research for studying various reaction mechanisms and exploring new synthetic pathways. Its unique structure and reactivity make it an ideal candidate for investigating novel chemical transformations and developing innovative synthetic methods.

Upstream product

• 16839-97-7 2-methoxythiophene 

Downstream Products

• 35087-46-8 2-methoxythiophene-5-carbaldehyde 
• 29212-22-4 5-methoxythiophene-2-carboxylic acid 
• 1431042-97-5 1-(5-((4-((5-methoxythiophen-2-yl)ethynyl)phenyl)ethynyl)thiophen-2-yl)ethanone 
• 1431043-00-3 2-methoxy-5-((4-((5-methylthiophen-2-yl)ethynyl)phenyl)ethynyl)thiophene 
• 1431042-95-3 ((4-((5-methoxythiophen-2-yl)ethynyl)phenyl)ethynyl)trimethylsilane 

Relevant articles and documents

ARYLAMIDES AND METHODS OF USE THEREOF

The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Rational Design of Azothiophenes—Substitution Effects on the Switching Properties

A series of substituted azothiophenes was prepared and investigated toward their isomerization behavior. Compared to azobenzene (AB), the presented compounds showed red-shifted absorption and almost quantitative photoisomerization to their (Z) states. Furthermore, it was found that electron-withdrawing substitution on the phenyl moiety increases, while electron-donating substitution decreases the thermal half-lives of the (Z)-isomers due to higher or lower stabilization by a lone pair–π interaction. Additionally, computational analysis of the isomerization revealed that a pure singlet state transition state is unlikely in azothiophenes. A pathway via intersystem crossing to a triplet energy surface of lower energy than the singlet surface provided a better fit with experimental data of the (Z)→(E) isomerization. The insights gained in this study provide the necessary guidelines to design effective thiophenylazo-photoswitches for applications in photopharmacology, material sciences, or solar energy harvesting applications.

Synthesis, Nicotinic Acetylcholine Receptor Binding, and in Vitro and in Vivo Pharmacological Properties of 2′-Fluoro-(substituted thiophenyl)deschloroepibatidine Analogues

The synthesis, nAChR in vitro and in vivo pharmacological properties of 2′-fluoro-3′-(substituted thiophenyl)deschloroepibatidine analogues (5a-f, 6a-d, and 7a-c) are presented herein. All had subnanomolar affinity at α4β2*-nAChRs. Contrary to lead structure epibatidine, a potent nAChR agonist, all were potent α4β2- and α3β4-AChR antagonists in an in vitro functional assay. In vivo, the compounds were also nAChR antagonists with various degrees of agonist activity. Compounds 5e, 5f, 6a, 6c, 6d, and 7c had no agonist effects in the tail-flick, hot-plate, hypothermia, or spontaneous activity tests, whereas 5a-d, 7a and 7b did not have agonist activity in the tail-flick and hot-plate tests but, like varenicline, were agonists in the hypothermia and spontaneous activity tests. Compound 6b had agonist activity in all four in vivo tests. All the compounds were antagonists of nicotine-induced antinociception in the tail-flick test, and all except 5c, 5d, 5f, and 6b were antagonists of nicotine-induced antinociception in the hot-plate test. Compound 7c, which had a Ki = 0.86 nM in the binding assay similar potency at α4β2/α3β4 with selectivity relative to α7 nAChRs, had an AD50 value of 0.001 μg/kg in the tail-flick test with no agonist activity in the in vitro or in vivo test had one of the more interesting profiles.

INDOLE CARBOXAMIDES AS IKK2 INHIBITORS

The invention is directed to novel indole carboxamide compounds. Specifically, the invention is directed to compounds according to formula (I): wherein R1, R2, R3, R4, and m are as defined herein. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Thiophene Systems. 13. The Synthesis of Novel Thienopyranones

The syntheses and spectral properties of novel dimethyl-substituted thieno-, - and pyranones are described.The uv spectra of the three systems are distinctly different as supported by HOMO/LUMO calculations. 5,6-Dihydro-5,5-dimethyl-7H-thienopyran-7-one (10) and 5,6-dihydro-6,6-dimethyl-4H-thienopyran-4-one (20) represent the first members of these thienopyranone ring systems.